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Department of Medicine–Hypertension, Cleveland, Ohio, USAHypertension is common in patients with chronic kidney disease (CKD) and is the most important modi-
ﬁable risk factor for CKD progression and adverse cardiovascular events in these patients. Diagnosis and
successful management of hypertension are critically dependent on accurate blood pressure (BP) mea-
surement. This is most relevant to CKD patients, in whom BP control is difﬁcult to achieve and in whom
early antihypertensive treatment is imperative to prevent kidney and cardiovascular complications.
Accumulated data indicate that ambulatory blood pressure monitoring (ABPM) is better in detecting hy-
pertension than ofﬁce BP measurement. ABPM is also a superior prognostic marker compared with ofﬁce
BP and has successfully identiﬁed hypertensive CKD patients at increased risk. Additionally, ABPM pro-
vides information on circadian BP variation and short-term BP variability, which is associated with car-
diovascular and renal outcomes. This paper reviews the evidence for the usefulness of ABPM in detection
and management of hypertension in CKD patients and discusses our current understanding of the path-
ophysiology of altered circadian BP rhythm and variability in CKD and the role of abnormal BP patterns
detected by ABPM in relation to outcomes in CKD. In addition, this Review examines the emerging role of
antihypertensive chronotherapy to tailor BP management to the circadian BP pattern abnormality detected
by 24-hour ABPM.
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CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).H ypertension is a common problem in patients withCKD, and its incidence and prevalence increase
with declining glomerular ﬁltration rate (GFR).1 Among
individuals with hypertension, elevated systolic BP is
associated with incident CKD and a more rapid decline in
renal function.2 Based on data from the US Renal Data
System, it is estimated that hypertension occurs in about
23.3% of individuals without CKD and 35.8% of stage 1,
48.1% of stage 2, 59.9% of stage 3, and 84.1% of stages
4 and 5 CKD patients.1 Hypertension is also the single
most powerful risk factor for cardiovascular (CV) disease.
In clinical practice, the diagnosis of hypertension as well
as decisions regarding management of the elevated BP
has been based on BP measurements made in the clinic.
Ambulatory blood pressure monitoring (ABPM) has
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published online 4 June 2016and management of hypertension both in clinical
practice and in the research setting. ABPM allows serial
BP measurements at speciﬁc time intervals throughout a
24-hour period, thereby providing a better assessment
of the normal ﬂuctuations in BP levels associated with
daily activities and sleep. In this regard, ABPM is
particularly useful in evaluating the patient with highly
variable BP with wide discrepancies between the BP
readings obtained in the clinic and outside the clini-
cian’s ofﬁce. In addition, accumulated evidence from
longitudinal studies in the general population as well as
in patients with hypertension has consistently shown
that ambulatory BP (ABP) is superior to ofﬁce BP for
prediction of clinical outcome.3 It has also proved useful
in the treatment of hypertensive patients, providing a
better guide for monitoring adequacy of antihyperten-
sive therapy in patients with CKD.Physiology of BP Variability
BP may be viewed as a continuous variable that ﬂuc-
tuates throughout the day and night and follows a
circadian rhythm with levels rising during daytimeKidney International Reports (2016) 1, 94–104
Figure 1. Various factors affecting the overall degree of blood
pressure variability in a given individual.
MT Velasquez et al.: Ambulatory BP in CKD REVIEWand falling during sleep. The physiological control of
systemic arterial pressure is tightly regulated and in-
volves a complex interplay of multiple mechanisms
that act to maintain arterial pressure at a relatively
constant level. Any inciting stimulus or activity that
raises BP by 1 or more mechanisms is opposed by
counterregulatory mechanisms that lower BP.
Conversely, any intervention or agent that acts to
lower BP is countered by mechanisms that oppose or
limit the action of the primary agent.
Circadian BP variation has been recognized for
decades and has been documented in several studies
using either invasive or noninvasive BP recorders in
unrestricted or ambulant subjects.4–8 Typically, BP is
highest mid-morning at 10 AM and then falls pro-
gressively throughout the remainder of the day, and BP
is lowest at 3 AM and begins to rise again during the
early hours of the morning before waking.7 The daily
BP variation appears to be mediated by the circadian
rhythm of sympathetic tone, linked to changes in the
waking–sleeping cycle.8 The morning surge in BP may
be related to increased a-sympathetic vasoconstrictor
activity in the morning.9 The fall in BP during sleep is
associated with a decrease in sympathetic activity that
corresponds to the stages of non–rapid eye movement
(NREM) sleep.10 However, during REM sleep, which is
associated with dreaming, BP and sympathetic tone is
increased, returning to the levels observed during
wakefulness.10
Cortisol secretion also follows a circadian rhythm
with the plasma cortisol level rising during the early
morning until the waking hours and then falling
gradually during the day.11 Increased sensitivity of
blood vessels to norepinephrine accompanies an
increased plasma cortisol level, suggesting that cortisol
is another contributory factor to the early-morning BP
surge. A diurnal pattern for renin and aldosterone has
also been described.12,13 Plasma renin activity (PRA)
increases during the early hours of the morning,
peaking at 8 AM, and gradually decreases during the
day, reaching its nadir at 4 PM, followed by a gradual
increase overnight. Plasma levels of aldosterone follow
a diurnal pattern similar to that of renin, with an in-
crease during the early hours of the morning that peaks
just before or during the waking hours.12 Of interest is
the observation that PRA levels are closely and
temporally related to the pattern of sleep cycle. When
sleep cycles were complete, declining PRA levels
coincided with REM sleep phases and increasing levels
with NREM sleep phases. Spontaneous and provoked
awakenings blunt the rise in PRA normally associated
with NREM sleep.13 The nocturnal oscillations in PRA
closely reﬂect the pattern of sleep stage distribution
and are modiﬁed when sleep is interrupted. TheseKidney International Reports (2016) 1, 94–104observations suggest that a common regulatory mech-
anism within the central nervous system controls both
PRA oscillations and the REM–NREM sleep alternation.
The diurnal BP rhythm is affected by the cycle of
sleep–awake activity and adapts to a shifted phase of
activity and sleep as has been observed in shift
workers.14–16 For example, day workers show a normal
circadian rhythm with a fall in both systolic and dia-
stolic BP at night. This pattern was reversed in night
workers. Among workers who rotated shifts, BP fol-
lows the cycle of rest and activity rather than the time
of day.
Other factors that affect BP variability include age,
gender, ethnicity, baroreﬂex sensitivity, body mass
index, sodium intake, smoking, and alcohol intake, as
well as the level of BP itself.17–28 The overall degree of
BP variability in a given individual is likely the result
of the complex interaction of neural and humoral
changes and the superimposed effects of biological and
behavioral as well as environmental factors (Figure 1).
BP Variability and Altered Circadian BP Patterns
in CKD Patients
Several cross-sectional and prospective studies using
24-hour ABPM have demonstrated alterations in BP
variability and circadian BP patterns in patients with
CKD (Table 1). In a study of 803 untreated hypertensive
patients with varying degrees of kidney function,
Manios et al.29 showed that the 24-hour rate of systolic
BP variation (a measure of short-term BP variability)
was signiﬁcantly higher in patients with reduced kid-
ney function (estimated GFR [eGFR] < 60 ml/min per
1.73 m2) than in those with an eGFR $ 60 ml/min per
1.73 m2. In a larger study of 10,271 Spanish hyper-
tensive patients with and without CKD, Mojón and
colleagues30 showed that those with CKD (deﬁned
by eGFR < 60 ml/min per 1.73 m2, urine albumin-
to-creatinine ratio $ 30 mg/g, or both) had higher95
Table 1. Altered BP variability and ambulatory BP pattern in CKD patients
Study design Patients (n) ABP proﬁles/outcomes References
Cross-sectional HTN pts (n ¼ 803) 24-hour rate of SBP variation higher in pts with eGFR <60 Manios et al.29
Cross-sectional HTN pts (n ¼ 10,271) Higher prevalence of non-dipping in pts with CKD (eGFR <60) versus pts with no CKD
(eGFR >60); higher nocturnal SBP and lower DBP in pts with CKD versus pts with no CKD
Mojón et al.30
Cross-sectional African Americans (n ¼ 1022)
with and without CKD
Higher average 24-hour BP variability in pts with CKD Tanner et al.31
Cross-sectional HTN pts (n ¼ 328) Higher average 24-hour BP variability in pts with reduced eGFR Mulè et al.32
Cross-sectional CKD pts (n ¼ 14,382)
(stages 1–5)
Higher daytime and nighttime SBP and DBP variability Gorostidi et al.33
Prospective (f/u 2 yr) CRI pts (n ¼ 68) Blunted nocturnal BP fall; decline in creatinine clearance correlated with nocturnal DBP fall Timio et al.34
Prospective (f/u 3.2 yr) CRI pts (n ¼ 322) Decline in eGFR in non-dippers; stable eGFR in dippers Davidson et al.37
Prospective (f/u 3.5 yr) CKD pts (n ¼ 217) Non-dipping associated with increased risk of ESRD and total mortality Agarwal and Andersen38
Prospective Hypertensive CKD African
Americans (n ¼ 617)
24-hour SBP predicted both renal and CV outcomes Gabbai et al.39
Prospective (f/u 3.5 yr) African Americans (n ¼ 603) 10% higher nocturnal dipping associated with decreased risk of CKD
(eGFR <60) and lower annual rate of eGFR decline
McMullan et al.40
ABP, ambulatory blood pressure; BP, blood pressure; CKD, chronic kidney disease; CRI, chronic renal insufﬁciency; CV, cardiovascular; DBP, diastolic blood pressure; eGFR, estimated
glomerular ﬁltration rate; ESRD, end-stage renal disease; f/u, follow-up; HTN, hypertension; pts, patients; SBP, systolic blood pressure.
REVIEW MT Velasquez et al.: Ambulatory BP in CKDsystolic ABP particularly at night but lower diastolic
BP than those without CKD (eGFR > 60 ml/min per
1.73 m2). Furthermore, the prevalence of both non-
dipping and rising nocturnal BP patterns increased
with increasing severity of CKD.
Other groups have reported similar results of
increased 24-hour BP variability in patients with CKD31
and hypertensive patients with reduced kidney func-
tion and microalbuminuria.32 Gorostidi et al.33 con-
ducted a cross-sectional analysis of a large sample of
14,382 Spanish hypertensive patients with no CKD and
with stage 1 to stage 5 CKD and showed that BP vari-
ability assessed by SD of mean daytime and nighttime
systolic BP (SBP) and diastolic blood pressure (DBP)
was signiﬁcantly higher in CKD patients than in those
without CKD. This association was stronger for SBP
than for DBP and for nighttime than for daytime BP.
Several prospective studies also demonstrate a close
association between blunted nocturnal BP fall or
non-dipping and reduced kidney function in CKD
patients. Timio et al.34 prospectively studied 27
normotensive and 41 hypertensive patients with stable
CKD, 28 matched healthy subjects, and 47 patients with
essential hypertension without kidney disease. After a
follow-up of 24 months, both the normotensive and the
hypertensive patients with CKD showed an alteration
in the 24-hour ABP with signiﬁcantly blunted
nocturnal BP reduction as compared with the respec-
tive control groups. The same investigators extended
their observations in 48 hypertensive patients with
chronic renal insufﬁciency who were followed for
3 years and observed that the non-dippers had a faster
rate of creatinine clearance decline than the dippers.35
Moreover, the increase in urinary protein excretion
was higher in the non-dipper group than in the dipper
group, indicating that the non-dipping pattern of ABP96can be associated with a faster progression of renal
insufﬁciency in renal hypertensives. Kanaoka et al. also
found signiﬁcant positive relationships between uri-
nary albumin excretion rate and 24-hour, daytime, and
nighttime ambulatory SBP.36
Decreased diurnal BP variation has been shown by
Davidson et al.37 to be associated with a subsequent
decline in kidney function that is independent of SBP
load and other known risk factors. In another prospec-
tive study of 217 veterans with CKD followed for a me-
dian of 3.5 years, Agarwal and Andersen38 showed that
non-dipping is associated with increased risk of com-
posite kidney end point of end-stage renal disease
(ESRD) and total mortality. In a large cohort of 617 hy-
pertensive CKD patients enrolled in the African Amer-
ican Study of Kidney Disease and Hypertension (AASK)
who were followed for a median period of 5 years,
Gabbai et al.39 also demonstrated that 24-hour SBP pre-
dicts both kidney and CV outcomes. Further analyses
revealed that both daytime and nighttime SBP levels
were predictive of renal and CV outcomes. A prospective
study involving 603 African Americans enrolled in the
Jackson Heart Study with normal baseline kidney
function showed that loss of nocturnal BP dipping and
not morning BP surge is associated with risk of CKD.40
Collectively, these studies suggest that nocturnal
non-dipping is a common feature of altered circadian
BP rhythm in CKD patients, which may partly
contribute to the deterioration of kidney function in
such patients.
Another important abnormal ABP pattern is
“masked hypertension.” This phenomenon, also called
“reverse white-coat hypertension” or “white-coat
normotension” and described by Pickering,41 refers to
individuals having normal clinic BP levels but
elevated ABPM levels and is commonly found in CKDKidney International Reports (2016) 1, 94–104
MT Velasquez et al.: Ambulatory BP in CKD REVIEWpatients. In a cross-sectional study, Pogue et al.42
examined clinic BP and ABP patterns and their
associations with target organ damage in 617
African Americans with hypertensive kidney disease.
Masked hypertension was deﬁned by elevated
daytime ($135/85 mm Hg) or elevated nighttime
($120/70 mm Hg) ABP in those with controlled clinic
BP (<140/90 mm Hg); non-dipping was deﬁned by
a #10% decrease in mean nighttime SBP; reverse
dipping was deﬁned by a higher nighttime than
daytime SBP. Of the 617 participants with both clinic
BP and ABP, 80% had a non-dipping or reverse dip-
ping proﬁle. Of the 377 participants with controlled
clinic BP (61%), 70% had masked hypertension.
Moreover, target organ damage such as proteinuria
and left ventricular hypertrophy were more common
in those with elevated nighttime BP, masked hyper-
tension, or sustained hypertension, compared with
those with controlled clinic BP or white-coat hyper-
tension. A meta-analysis involving 980 CKD patients
showed that the overall prevalence of masked hyper-
tension was 8.3% and of white-coat hypertension was
18.3%.43 Of great prognostic importance is the masked
hypertension, which, like nocturnal BP non-dipping,
is also associated with increased risk of progression
to ESRD and total mortality in CKD patients.38 In
another study of 333 veterans with CKD, Agarwal
et al.44 prospectively evaluated the prevalence of
masked uncontrolled hypertension using 3 deﬁnitions of
hypertension (daytime hypertension $135/85 mm Hg;
either nighttime hypertension $120/70 mm Hg or
daytime hypertension; and 24-hour hypertension$130/
80 mm Hg) or by home BP monitoring
(hypertension $135/85 mm Hg). In this study, the
prevalence of masked uncontrolled hypertension
was 26.7% by daytime ABP, 32.8% by 24-hour ABP,
56.1% by daytime or nighttime ABP, and 50.8% by
home BP. Thus, masked uncontrolled hypertension
is common in CKD patients, and its diagnosis by ABP
is reproducible with 75% to 78% agreement between 2
repeated measurements.Table 2. Altered ambulatory BP proﬁle and cardiovascular events in pati
Study design Patients (n)
Cross-sectional African Americans with CKD
(n ¼ 617)
Proteinuria a
Cross-sectional CKD pts (n ¼ 540) Reverse dipper BP pattern
Cross-sectional CKD pts (n ¼ 1219) BP load and AB
nighttime SBP
Longitudinal
(follow-up >4 yr)
Veterans with CKD (n ¼ 274) Rate of growth of LVMI
BP and 24-hour
Cross-sectional CKD pts (n ¼ 1492) Masked hyperte
higher
ABP, ambulatory blood pressure; BP, blood pressure; CKD, chronic kidney disease; CV, cardiova
hypertrophy; LVMI, left ventricular mass index; pts, patients; SBP, systolic blood pressure; TO
Kidney International Reports (2016) 1, 94–104ABPM and CV Events in CKD
Recent studies have evaluated target organ damage and
CV events associated with ABP patterns in patients
with CKD45–48 (Table 2). In an observational ABPM
study of 540 Chinese CKD patients, Wang and associ-
ates45 reported that patients with reversed dipper BP
pattern had worse kidney function and CV damage
compared with patients with a dipper BP pattern.
These investigators46 further studied a larger cohort of
1219 patients with CKD, which included 432 nondia-
betic CKD patients without hypertension, 565 nondia-
betic CKD patients with hypertension, and 222 diabetic
patients. They found that BP load and ABP levels both
were independently correlated with left ventricular
mass index (LVMI), eGFR, and proteinuria in all groups
of CKD patients. Furthermore, nighttime SBP load
correlated with LVMI in nondiabetic CKD patients with
or without hypertension.
Recent data also suggest an association between
masked hypertension and CV target organ damage in
CKD patients.47,48 In a longitudinal study of 274 vet-
erans with CKD followed for about 4 years, Agarwal47
showed that both clinic BP and 24-hour ABP were
associated with LVMI and its rate of growth over time.
Moreover, different categories of hypertension,
namely, masked uncontrolled hypertension, controlled
hypertension, and uncontrolled hypertension, were
associated with increasing LVMI when diagnosed by
24-hour ambulatory and awake BP but not sleep BP. In
another study, Drawz et al.48 performed 24-hour ABPM
in 1492 men and women with CKD enrolled in the
Chronic Renal Insufﬁciency Cohort (CRIC) Study, who
were categorized into 4 groups—controlled BP and
white-coat, masked, and sustained hypertension—on
the basis of clinic and 24-hour ABP. In this study,
masked hypertension was independently associated
with low eGFR, higher proteinuria, and higher LVMI
and pulse wave velocity compared with controlled BP.
The association between masked hypertension and
lower eGFR was observed only in those participants
with elevated nighttime BP.ents with CKD
ABP proﬁles/outcomes References
nd LVH more common in patients with elevated
nighttime BP and masked hypertension
Pogue et al.42
closely related to worse renal function and severe CV damage Wang et al.45
P levels correlated with LVMI, eGFR, and proteinuria;
load correlated with TOD in pts with nondiabetic CKD
Wang et al.46
was rapid in ﬁrst 2 years and plateaued subsequently; clinic
ABP were associated with LVMI and its growth over time
Agarwal47
nsion was independently associated with low eGFR,
proteinuria, and higher LVMI and pulse wave
Drawz et al.48
scular; eGFR, estimated glomerular ﬁltration rate; LV, left ventricular; LVH, left ventricular
D, target organ damage.
97
Table 3. Altered ambulatory BP proﬁle and cardiovascular events in patients with end-stage renal disease
Study design Patients (n) ABP proﬁles/outcomes References
Prospective Hypertensive HD pts (n ¼ 57) Elevated nocturnal systolic BP and elevated PP were
independently associated with CV mortality
Amar et al.49
Prospective HD patients (n ¼ 80) Nocturnal BP non-dipping positively associated with CV events and CV mortality Liu et al.50
Prospective Nondiabetic HD pts (n ¼ 168) Night/day systolic BP ratio strongly predicts total and CV mortality Tripepi et al.51
Cross-sectional ESRD pts undergoing
APD (n ¼ 20) versus CAPD (n ¼ 28)
LVMI higher in diastolic non-dippers compared to dippers; non-dipper
diastolic BP pattern associated with LVMI
Atas¸ et al.52
ABP, ambulatory blood pressure; APD, automated peritoneal dialysis; BP, blood pressure; CAPD, continuous ambulatory peritoneal dialysis; CV, cardiovascular; ESRD, end-stage renal
disease; HD, hemodialysis; LVMI, left ventricular mass index; PP, pulse pressure; pts, patients.
Table 4. Putative mechanisms of altered BP variability in CKD
1. Increased sodium and ﬂuid volume retention
2. Impaired baroreceptor sensitivity
3. Altered sympathetic nervous system activity
4. Activation of the renin–angiotensin–aldosterone system
5. Endothelial dysfunction
6. Oxidative stress
7. Inﬂammation
8. Increased arterial stiffness
REVIEW MT Velasquez et al.: Ambulatory BP in CKDABPM and CV Events in ESRD
As in patients with CKD, a number of studies have
examined the BP variability and circadian BP patterns
and their relationships to CV events or risks in patients
with ESRD49–52 (Table 3). In a prospective study of 57
treated hypertensive hemodialysis patients, Amar
et al.49 reported that elevated nocturnal SBP and
elevated pulse pressure were independently associated
with CV mortality. Similarly, in 80 hemodialysis
patients, Liu et al.50 have shown that nocturnal BP non-
dipping was positively associated with CV events and
CV mortality.
In another prospective study of 168 nondiabetic
hemodialysis patients without a prior history of CV
events, Tripepi et al.51 have shown that the night/day
SBP ratio was shown to be a stronger predictor of total
mortality and CV mortality. As in hemodialysis
patients, hypertension and non-dipping BP pattern
have also been shown to be associated with left ven-
tricular hypertrophy in peritoneal dialysis patients.
Atas¸ et al.52 compared the ABPM proﬁle and LVMI in
2 groups of ESRD patients undergoing either auto-
mated peritoneal dialysis or continuous ambulatory
peritoneal dialysis and showed that LVMI was
signiﬁcantly higher in diastolic non-dippers compared
to dippers.
Mechanisms of Altered BP Variability and
Circadian Rhythm in CKD
The mechanisms underlying the altered BP variability
and circadian rhythm in CKD are incompletely under-
stood. Several factors or mechanisms, including
increased sodium and ﬂuid volume retention, impaired
baroreceptor sensitivity, altered sympathetic nervous
system activity, activation of the renin–angiotensin
system (RAS), endothelial dysfunction, oxidative
stress, inﬂammation, and increased arterial stiffness,
have been proposed to explain the altered BP circadian
rhythm (Table 4 and Figure 2).
Increased sodium and ﬂuid retention due to impaired
ability of the diseased kidney has been proposed as the
major factor contributing to nocturnal hypertension
and non-dipping BP pattern in CKD.53 Nocturnal98hypertension is thought to compensate for the sodium
retention during the daytime and enhanced pressure
natriuresis during the night. Baroreﬂex dysfunction
resulting in impaired BP regulation could contribute to
increased BP variability in CKD.54–66 Sympathetic ner-
vous system overactivity is well documented in patients
with chronic kidney failure.57–62 Increased sympathetic
nervous system activity has been shown to be closely
associated with blunted nocturnal BP reduction in
hypertensive patients with diabetic nephropathy.62 Of
note is the ﬁnding by Okuguchi et al.63 in a study of
salt-sensitive patients and essential hypertensive
patients, who showed that salt loading converted the
circadian BP pattern from dippers to non-dippers, an
effect that was associated with an increase in the
nighttime/daytime ratio of urinary noradrenaline
excretion. The failure of nocturnal BP to fall is thought
to be related to the lack of nocturnal decrease in sym-
pathetic nervous activity.
Circadian BP variability has also been linked to RAS
activity, since it is known that renin and angiotensin II
levels are inﬂuenced by circadian rhythms.64,65 Local
RAS activity in the kidneys has been suggested to
contribute to BP variability in patients with primary
hypertension.66 Intrarenal RAS activation has also been
implicated in the abnormal circadian BP changes in
CKD.67
Endothelial dysfunction is a common event in the
development of hypertension,68 and in all stages of
CKD,69,70 and is closely associated with abnormal
circadian BP variation and non-dipping pattern.71,72 In
hypertensive patients, nocturnal BP is elevated and
endothelial function deteriorates in parallel with a
decline in kidney function.73Kidney International Reports (2016) 1, 94–104
Figure 2. Mechanisms of altered blood pressure variability and circadian rhythm in chronic kidney disease.
MT Velasquez et al.: Ambulatory BP in CKD REVIEWThere is evidence that suggests a role of the
endothelin-1 (ET-1) system in diurnal BP variation. A
circadian rhythm of plasma ET-1 has been observed in
healthy volunteers74 and in patients with CKD.75 One
study has shown that the circadian clock protein
period 1 regulates ET-1 mRNA and protein in the
kidney, and this contributes to the regulation of renal
sodium transport and BP.76 Further support for the
contribution of the ET-1 system in hypertension and
loss of nocturnal BP dipping in CKD is provided by the
recent studies of Dhaun and co-investigators77
showing that treatment with the selective ETA recep-
tor antagonist sitaxentan for 6 weeks increased the
nocturnal dip in both SBP and DBP in patients with
CKD.
Oxidative stress with increased production of reac-
tive oxygen species plays a causal role in the devel-
opment of hypertension78 and contributes to kidney
damage and progression of CKD.79,80 Increased reactive
oxygen species formation by peripheral blood mono-
nuclear cells has been observed in hypertensive
patients exhibiting exaggerated BP dipping and
morning BP surge.81 Serum markers of oxidative stress,
such as asymmetric dimethylarginine and nitro-
tyrosine, are increased in non-dipper hypertensive
patients compared with dipper hypertensive patients.82
Inﬂammation has also been suggested to promote
increased BP variability. Circulating inﬂammatory
markers, such as C-reactive protein or tumor necrosis
factor-a, have been shown to be positively correlated
with 24-hour ABP variability in healthy adults83 and in
African Americans,84 as well as in hypertensive
patients, independent of absolute BP levels.85 Inﬂam-
matory mediators are frequently elevated in CKD,86–88
which could contribute to increased BP variability
through accelerated peripheral artery disease observed
in CKD.89,90 Studies are needed to determine whether
controlling inﬂammation could reduce BP variability
and the adverse CV consequences in CKD.Kidney International Reports (2016) 1, 94–104Enhanced aortic stiffening is well documented in
patients with CKD91–93 and is closely related to
increased short-term or 24-hour BP.94–96 The mecha-
nism for increased arterial stiffness in CKD and ESRD is
likely multifactorial.97–100 Vascular remodeling with
changes in arterial wall composition and elasticity and
arterial calciﬁcation, a pathological process linked to
abnormal mineral metabolism in CKD, are major factors
implicated in arterial stiffening.99 Other mechanisms or
factors, such as RAS activation, ET-1, endothelial
dysfunction, oxidative stress, and inﬂammation, as
well as the anti-aging molecule Klotho,100 are also
implicated in this process.
ABPM and Effects of Kidney Transplantation
Only a few studies have examined the effects of kidney
transplantation (KTx) on circadian BP proﬁle and BP
control in ESRD patients. Gatzka et al.101 evaluated 24-
hour ABP circadian proﬁle in 45 patients after suc-
cessful KTx and observed that the prevalence of dippers
increased from 27% in the early phase (<7 months) to
73% in the late phase ($1 year) after KTx. The longer
the time after KTx, the more marked was the decrease of
BP during sleep. The improvement in nocturnal BP
dipping pattern effect did not appear to be related to the
concomitant antihypertensive or immunosuppressive
therapy. Covic et al.102 compared the ABP proﬁles
recorded at 1 month before and 1 month and >1 year
after successful KTx in 20 living kidney transplant re-
cipients and observed that at 1 month post-transplant,
KTx had little or no effect on abnormal circadian
pattern in most recipients. However, at 1 year post-
transplant, KTx resulted in a signiﬁcant improvement
of the circadian BP proﬁle. This effect is mainly deter-
mined by the prevailing level of kidney function and
by the initial pre-transplantation dipping proﬁle.
Wadei et al.103 analyzed ABPM proﬁle in relation to
allograft function in 119 kidney transplant recipients
after 1 year of transplantation. Nocturnal fall in SBP99
REVIEW MT Velasquez et al.: Ambulatory BP in CKDand GFR was related to worse allograft function in
those with abnormal circadian BP change. Additional
studies in a subgroup of 36 kidney recipients who were
followed for 3 to 4 years showed that the patients with
nocturnal non-dipping or reverse dipping patterns had
signiﬁcantly greater loss of kidney function compared
with those with normal dipping pattern.104 These
results indicate that kidney transplant patients with
abnormal circadian BP pattern at 1 year are at increased
risk for kidney function loss in subsequent years.
More recently, Lee et al.105 prospectively evaluated
the impact of KTx on the status of hypertension and
circadian rhythm in 48 ESRD patients before and 1 year
after KTx. After KTx, the mean 24-hour ABP value did
not change, but the proportion of patients taking
antihypertensive drugs and the pill number signiﬁ-
cantly decreased. In contrast, the mean nocturnal fall in
SBP signiﬁcantly decreased and was associated with
inferior allograft function during follow-up. Taken
collectively, the results of these studies suggest that the
overall impact of KTx on circadian BP pattern may vary
depending on the time interval after transplantation,
prevailing allograft function, and concomitant use of
antihypertensive or immunosuppressive medications.
Longer prospective studies involving a larger number
of kidney transplant patients are needed to determine
whether restoration of normal BP circadian pattern will
confer better allograft outcome in the long term.
ABP and Effects of Antihypertensive Treatment
in CKD
Most clinical trials on the effects of various classes of
antihypertensive medications on 24-hour ABP have
been conducted in hypertensive patients without
CKD.106–110 Generally, calcium channel blockers such as
nifedipine are more effective with bedtime than morn-
ing dosing.108 Given that the RAS follows a circadian
rhythm and activates during nighttime sleep, a series of
clinical studies by Hermida et al. have been conducted
that show that bedtime dosing of angiotensin-
converting enzyme inhibitors or angiotensin receptor
blockers exerts a more marked effect on asleep than
awake BP means in hypertensive patients.109
Only a few studies have evaluated the effects of
daytime versus bedtime administration of antihyper-
tensive agents in patients with CKD, and the results of
these studies are mixed.110–114 In an 8-week uncon-
trolled trial of 32 CKD patients, Minutolo et al.111
showed that changing the timing of antihypertensive
medication dosing from morning to evening decreased
the night/day ratio of mean ABP in 93.7% of patients
and restored normal circadian rhythm in 87.5%.
Moreover, proteinuria also was reduced with evening
administration of antihypertensive medications. In a100randomized study of 661 hypertensive patients with
CKD, Hermida et al.110 compared the effects on ABP
control of changing 1 or more of the daily antihyper-
tensive medications to bedtime versus giving all med-
ications upon awakening. The subjects randomized to
bedtime medication showed a better overall control of
BP on ABPM, greater reduction in mean asleep SBP,
and a lower proportion of non-dippers. Subjects ran-
domized to bedtime therapy also had greater reduction
in albuminuria compared to the control group. More
importantly, the group receiving bedtime dosing had a
signiﬁcant reduction in the composite outcome of CV
death, myocardial infarction, or stroke. The same group
of investigators112 reported similar results in a ran-
domized trial comparing bedtime treatment versus
conventional therapy in 448 hypertensive patients with
type 2 diabetes. After a median follow-up of 5.4 years,
patients ingesting $1 hypertension medication at
bedtime showed signiﬁcantly lower CV events than
subjects ingesting all medications upon awakening.
The patients treated at bedtime showed signiﬁcantly
lower sleep time BP mean and higher prevalence of
controlled ABP. However, one study in 147 former
participants of the African American Study of Kidney
Disease and Hypertension (AASK) with hypertensive
kidney disease failed to show nocturnal SBP reduction
with nightly antihypertensive drug dosing.113 The
reasons for the discrepant results are not clear but may
partly relate to differences in race, age, kidney func-
tion, nocturnal BP status, or duration of hypertension.
Another recent study by Wang et al.114 showed that
bedtime dosing of an ARB once daily was signiﬁcantly
more effective than awakening dosing in reducing
nighttime BP, proteinuria, and left ventricular mass in
CKD patients with non-dipping pattern. Further studies
are needed to determine whether other classes of anti-
hypertensive medications or interventions are superior
in controlling nocturnal hypertension in CKD patients.
Conclusion and Future Directions
In conclusion, a large body of evidence supports the
use and superiority of ABPM over clinic BP measure-
ments in making an accurate diagnosis and classiﬁca-
tion of hypertension, assessing target organ damage,
predicting outcomes, and evaluating response to ther-
apy in patients with CKD, in whom optimal BP control
is often difﬁcult to achieve. Numerous studies using
24-hour ABPM in hypertensive patients with and
without CKD, in ESRD patients, and in kidney trans-
plant patients have identiﬁed high-risk individuals
with altered BP variability and circadian BP patterns,
which have been shown to be associated with target
organ damage or adverse kidney and CV outcomes. In
hypertensive patients with and without CKD, severalKidney International Reports (2016) 1, 94–104
MT Velasquez et al.: Ambulatory BP in CKD REVIEWmeasures of BP variability are increased and have been
shown to be closely associated with kidney injury
(e.g., reduced eGFR or albuminuria as well as CV target
organ damage). The most important circadian BP pat-
terns frequently observed in these patients are blunted
nocturnal BP fall (non-dipping) and elevated nighttime
BP (nocturnal hypertension). Both non-dipping
status and nocturnal hypertension are associated with
target organ damage and CV risk. Another important
abnormal ABP pattern commonly observed in CKD
patients is masked hypertension, which has also been
shown to be strongly associated with CV and target
organ damage.
Recent work has focused on antihypertensive chro-
notherapy based on ABP proﬁle in the management of
hypertensive patients with CKD. Dosing 1 or more
antihypertensive medications at bedtime has been
shown to improve BP control, lower nocturnal BP, and
reduce the risk of CV events in a few studies but not in
others.110,111,113,114 Therefore, until more data in CKD
patients are available, caution is warranted in recom-
mending antihypertensive chronotherapy in CKD pa-
tients. Management of hypertension in CKD patients
should focus on choosing appropriate use of antihy-
pertensive drugs to reduce the level of nocturnal BP
and restore diurnal rhythm of BP. For example, one
important strategy is the timely use of diuretic therapy
alone or in combination with other antihypertensive
agents to treat nocturnal hypertension. More clinical
trials in CKD and ESRD patients are needed to deter-
mine whether chronotherapy targeting these ABPM
ﬁndings improves CV outcomes in the long term.
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